TCM
ALXN

Taal Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Taal Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$9.19M Buy
+50,000
New +$8.58M 7.52% 2

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Taal Capital Management's ALXN Position: Q2 2021 in Review

Taal Capital Management opened a new position in Alexion Pharmaceuticals (ALXN) in Q2 2021: 50,000 shares worth $9.19M. The stake represents 7.52% of the portfolio and ranks #2 among its holdings.

708 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Taal Capital Management held 50,000 shares of Alexion Pharmaceuticals worth $9.19M as of Q2 2021.
  • Alexion Pharmaceuticals was a new Taal Capital Management position in Q2 2021.
  • Alexion Pharmaceuticals made up 7.52% of Taal Capital Management's portfolio in Q2 2021, its #2 holding.
  • 708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Taal Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.